Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?

被引:3
|
作者
Turkdogan, Sena [1 ]
Pusztaszeri, Marc [2 ]
Forest, Veronique-Isabelle [1 ]
Hier, Michael P. [1 ]
Payne, Richard J. [1 ]
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Dept Otolaryngol Head & Neck Surg, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada
关键词
thyroid cancer; thyroid nodule; Bethesda; molecular testing; FINE-NEEDLE ASPIRATIONS; UNDETERMINED SIGNIFICANCE; EXTRATHYROIDAL EXTENSION; SOLID VARIANT; CARCINOMA; CATEGORY; ATYPIA; SYSTEM; SUBCLASSIFICATION; CYTOLOGY;
D O I
10.3390/cancers12092563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The Bethesda classification system is a widespread tool used in the initial screening test for thyroid nodules. The system classifies the biopsy of the nodule into 6 categories, each with its associated malignancy risk and recommendations for management. Nodules classified as Bethesda III and IV are considered intermediate risk, and although Bethesda III nodules are more likely to be benign than Bethesda IV, our hypothesis is that out of those that are malignant, a subset may be more aggressive given their diverse cellular features. In this study we looked at 628 individuals who underwent surgery with a Bethesda III or IV nodule and compared the number of aggressive features found in those with confirmed malignancy. We discovered that Bethesda III nodules that were found to be malignant were more likely to have aggressive features, such as aggressive sub-types of thyroid cancer, spread of cancer beyond the thyroid capsule, and spread of cancer to the lymph nodes. Our results suggest that Bethesda III thyroid nodules may not as indolent as they seem, and these findings may affect management decisions in individuals with indeterminate thyroid nodules. The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [1] Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules
    Alyusuf, Ebtihal Y.
    Alhmayin, Lama
    Albasri, Eman
    Enani, Jawaher
    Altuwaijri, Hessa
    Alsomali, Nora
    Arafah, Maria A.
    Alyusuf, Zahra
    Jammah, Anwar A.
    Ekhzaimy, Aishah A.
    Alzahrani, Ali S.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [2] Does Bethesda Category Predict Aggressive Features in Malignant Thyroid Nodules?
    David A. Kleiman
    Toni Beninato
    Ashwin Soni
    Yiyan Shou
    Rasa Zarnegar
    Thomas J. Fahey
    [J]. Annals of Surgical Oncology, 2013, 20 : 3484 - 3490
  • [3] Does Bethesda Category Predict Aggressive Features in Malignant Thyroid Nodules?
    Kleiman, David A.
    Beninato, Toni
    Soni, Ashwin
    Shou, Yiyan
    Zarnegar, Rasa
    Fahey, Thomas J., III
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (11) : 3484 - 3490
  • [4] Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule
    Li, Fu
    Pan, Denghua
    Wu, Yuquan
    Peng, Jinbo
    Li, Qing
    Gui, Xiaolong
    Ma, Wei
    Yang, Hong
    He, Yun
    Chen, Junqiang
    [J]. DIAGNOSTIC CYTOPATHOLOGY, 2019, 47 (09) : 881 - 889
  • [5] AI diagnosis of Bethesda category IV thyroid nodules
    Yao, Jincao
    Zhang, Yanming
    Shen, Jiafei
    Lei, Zhikai
    Xiong, Jing
    Feng, Bojian
    Li, Xiaoxian
    Li, Wei
    Ou, Di
    Lu, Yidan
    Feng, Na
    Yan, Meiying
    Chen, Jinjie
    Chen, Liyu
    Yang, Chen
    Wang, Lipin
    Wang, Kai
    Zhou, Jianhua
    Liang, Ping
    Xu, Dong
    [J]. ISCIENCE, 2023, 26 (11)
  • [6] Risk Stratification of Bethesda III Category Thyroid Nodules
    Alseddeeqi, Eiman
    Mubarak, Rawia
    Altinoz, Ajda
    More, Yogesh
    Elomami, Abdulghani
    [J]. JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 9 (06) : 180 - 185
  • [7] Misleading Clinical Significance of Bethesda Category IV for Thyroid Nodules
    Buonocore, Darren
    Lin, Oscar
    Cohen, Jean Marc
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 135 - 135
  • [8] Misleading Clinical Significance of Bethesda Category IV for Thyroid Nodules
    Buonocore, Darren
    Lin, Oscar
    Cohen, Jean Marc
    [J]. MODERN PATHOLOGY, 2018, 31 : 135 - 135
  • [9] Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules
    Endo, Mayumi
    Peng, Jing
    Nabhan, Fadi A.
    Brock, Pamela
    Azaryan, Irina
    Long, Clarine
    Ryan, Laura E.
    Ringel, Matthew D.
    Sipos, Jennifer A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (09): : 2317 - 2324
  • [10] DICER1 Mutation in Bethesda III Thyroid Nodules
    Karimkhan, Afreen
    Xia, Rong
    Hindi, Issa
    Belovarac, Brendan
    Shafizadeh, Negin
    Sun, Wei
    Patel, Kepal
    Givi, Babak
    Hodak, Steven
    Simsir, Aylin
    Brandler, Tamar
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S320 - S321